Abemaciclib

Extended follow-up of a randomized phase 3 trial presented at the virtual San Antonio Breast Cancer Symposium showed the addition of abemaciclib to endocrine therapy continued to benefit certain patients with high-risk breast cancer.

The addition of abemaciclib to endocrine therapy significantly extended invasive DFS.

Data showed manageable and consistent side effects with combination abemaciclib and pembrolizumab, but produced a higher rate of transaminase elevations than individual treatments, according to a presentation at the virtual ASCO20 Annual Meeting.

Healio spoke with Roberto A. Leon-Ferre, MD, about recent approvals in breast cancer.

During the past decade, several key preclinical studies established the biologic rationale for targeting cyclin-dependent kinase 4/6 in women with hormone receptor-positive breast cancer.

Carey K. Anders, MD, medical director for the Center for Brain and Spine Metastasis at Duke Cancer Institute, discussed treatment options for brain metastasis across breast cancer, including HER2-positive, triple-negative or hormone receptor-positive disease.

In this video, Pooja Khandelwal, MD, an associate professor at the University of Cincinnati's Department of Pediatrics, discusses the latest in the treatment and study of graft-versus-host disease, including new innovations for the treatment of chronic cases.